COGT

Cogent Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cogentbio.com
Employees(FY) 138
ISIN US19240Q2012

Performance

-6.0%

-13.47%

-28.07%

-7.76%

+33.33%

YTD

+51.94%

Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of COGT 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of COGT

Stock Rank

Recent News & Updates

2024-12-09 07:00
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients(GlobeNewswire)
2024-12-08 18:00
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients(Globenewswire)
2024-12-08 12:00
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)(GlobeNewswire)
2024-12-07 23:00
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)(Globenewswire)
2024-11-05 09:00
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting(GlobeNewswire)
2024-11-04 20:00
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting(Globenewswire)
2024-10-23 07:00
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics(GlobeNewswire)
2024-10-22 19:00
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics(Globenewswire)
2024-10-20 09:39
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation(Simply Wall St.)
2024-10-09 08:03
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target(Insider Monkey)
2024-09-03 08:00
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis(GlobeNewswire)
2024-09-02 20:00
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis(Globenewswire)
2024-09-02 05:22
10 Best Small-Cap Healthcare Stocks To Buy Now(Insidermonkey)
2024-08-06 08:00
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results(GlobeNewswire)
2024-08-05 20:00
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results(Globenewswire)
2024-06-27 21:18
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting(Zacks)
2024-06-27 08:00
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial(GlobeNewswire)
2024-06-26 20:00
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial(Globenewswire)
2024-06-14 07:30
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)(GlobeNewswire)
2024-06-13 19:30
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)(Globenewswire)
2024-05-23 17:05
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer(GlobeNewswire)
2024-05-23 17:01
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting(GlobeNewswire)
2024-05-23 05:05
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer(Globenewswire)
2024-05-23 05:01
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting(Globenewswire)
2024-05-13 08:13
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth(Simply Wall St.)
2024-05-07 08:00
Cogent Biosciences Reports First Quarter 2024 Financial Results(GlobeNewswire)
2024-05-07 01:52
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024(Investorplace)
2024-05-06 20:00
Cogent Biosciences Reports First Quarter 2024 Financial Results(Globenewswire)
2024-04-09 09:00
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor(GlobeNewswire)
2024-04-08 21:00
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.